Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 4/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26762014 | 0.84 | RXRA (0.33) | NPC1RAB9A | |
| SCHEMBL23905240 | 0.81 | P2RX3 (0.38) | CRHR1P2RX3P2RX2HPGDS | |
| SCHEMBL12074836 | 0.79 | ALDH1A1 (0.42) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL23958814 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL23717026 | 0.76 | EGFR (0.38) | ALDH1A1CRHR1P2RX3P2RX2HPGDS | |
| SCHEMBL26762018 | 0.75 | PRNP (0.46) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL26577804 | 0.75 | PTGS2 (0.44) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL25113960 | 0.74 | CRHR1 (0.40) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL14904002 | 0.74 | HSD17B10 (0.43) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL20666239 | 0.73 | DYRK1A (0.48) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | ALDH1A1 2104/4885PRNP 290/4885MAPT 4609/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | ALDH1A1 2152/4885PRNP 267/4885MAPT 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.